|Description||BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.|
|Synonyms||BMS-193884; BMS 193884; BMS193884; 7ON53PV45J; SCHEMBL4204130; BDBM50091105; N-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
N-Despropyl-macitentan, an active metabolite of Macitentan, is a dual ET receptor antagonist with longer half-life than Macitentan. It has been proved to be eff...
IRL-2500, an indol derivative, has been found to be an endothelin B receptor antagonist that was once studied in hypertension.
SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.
BQ-3020 is a potent and selective ETB endothelin receptor agonist (Ki = 0.18 and 970 nM at human ETB and ETA receptors, respectively).
The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied...
Sarafotoxin S6a is an endothelin receptor agonist (EC50 = 7.5 and > 150 nM for contraction of pig coronary artery and guinea pig aorta, respectively).
Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...
Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.